Edwards Lifesciences Corp Investor Update at TCT Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Robbie Marcus, JPMorgan. Two questions. First, you had a question before about slowdown in structural heart and mitral. How much do you think is staffing versus maybe data? And is there a difference in the U.S. versus OUS with the positive overwhelmingly positive COAPT data with functional and MITRA-FR in Europe? And then second, how do we think about where you stand in enrollment for the functional trial? Scott Lim So as far as the slowdown in being able to do cases in structural heart disease, I think it absolutely is a real issue as it relates to our staffing in the United States. As far as it relates to data, I think the interventional cardiologists in the United States have really bought into the COAPT data who hasn't as much as in the heart failure community and in part because the heart failure world has shifted very rapidly even since the COAPT data came out with the new drugs that really are significant SGLT2 inhibitors and so forth. And so I think that needs more of both study and more education to really figure that out for them. I think we'll get there, but that is part of why it's not exploding even more. There is a difference in U.S. and the EU when I talk, particularly with my French colleagues.